<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02709798</url>
  </required_header>
  <id_info>
    <org_study_id>D99-2015(043)-TCM-4</org_study_id>
    <nct_id>NCT02709798</nct_id>
  </id_info>
  <brief_title>ShenFu Injection for Myocardial Protection in Patients With Acute ST Segment Elevation Myocardial Infarction</brief_title>
  <acronym>SF-STEMI</acronym>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Effect of Shenfu Injection on Reperfusion Injury in Patients With Acute ST Segment Elevation Myocardial Infarction After Primary Percutaneous Coronary Intervention: A Pilot Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Anzhen Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>China Resources Sanjiu Medical &amp; Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Beijing Anzhen Hospital</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate whether perioperative use of Shenfu Injection could
      reduce myocardial injury (enzymatic infarct size and infarct volume according to cardiac
      magnetic resonance imaging) in patients with STEMI after primary PCI
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 2016</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">November 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Infarct size</measure>
    <time_frame>immediately after admission (0 hour), and 6, 12, 18, 24, 48, and 72 hours after PCI, as well as 4±1days after PCI</time_frame>
    <description>Infarct size was assessed by measuring the area under the curve (AUC) of creatine kinase isoenzyme (CK-MB) within 72 hours after PCI and by performing cardiac magnetic resonance (CMR) imaging at 4±1days after PCI.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC of cardiac troponin I (cTnI)</measure>
    <time_frame>immediately after admission (0 hour), and 6, 12, 18, 24, 48, and 72 hours after PCI</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak value of CK-MB and cTnI</measure>
    <time_frame>72 hours after PCI</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ST segment resolution (%) according to ECG</measure>
    <time_frame>up to 24 hours after PCI</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left ventricular end-diastolic diameter (LVEDD), left ventricular end-systolic diameter (LVESD), and Left ventricular ejection fraction (LVEF)</measure>
    <time_frame>up to 28 days after PCI</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Main adverse cardiovascular and cerebrovascular events (MACCE, including death, non-fatal myocardial infarction, target vessel revascularization, stroke, new-onset severe heart failure, re-hospitalization for heart failure)</measure>
    <time_frame>up to 28 days after PCI</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>Shenfu Injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>80ml Shenfu Injection + 70ml 5% glucose injection), ivdrip, 30 minutes before PCI and 1-5 days (once a day) after PCI (6 times in total). Drug titration time should be no less than 30 minutes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5% Glucose Injection</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>150 ml 5% glucose injection, ivdrip, 30 minutes before PCI and 1-5 days (once a day) after PCI (6 times in total). Drug titration time should be no less than 30 minutes.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Shenfu Injection</intervention_name>
    <arm_group_label>Shenfu Injection</arm_group_label>
    <other_name>Shenfu Zhusheye</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5% Glucose Injection</intervention_name>
    <arm_group_label>5% Glucose Injection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age ≥18 and &lt;75 years;

          2. First-time acute anterior STEMI;

          3. The time from onset of ischemic symptom to the time of initial PCI balloon inflation
             ≤6 hours;

          4. &gt;0.1 mV ST segment elevation in at least two contiguous precordial leads according to
             electrocardiogram;

          5. Scheduled for primary PCI;

          6. The presence of left anterior descending branch (LAD) occlusion in proximal or middle
             segment with pre-PCI TIMI flow 0 or 1 according to baseline coronary angiogram;

          7. Written informed consent.

        Exclusion Criteria:

          1. Hypertrophic cardiomyopathy, aortic valve stenosis and/or regurgitation, pericarditis,
             or myocarditis;

          2. Cardiogenic shock, severe ventricular arrhythmia, serious heart failure (Killip class
             III and above) or mechanical complications;

          3. Patients after cardiopulmonary resuscitation (CPR) (including cardioversion);

          4. Patients who have already received thrombolytic therapy;

          5. Prior myocardial infarction or coronary artery bypass surgery;

          6. Known serious hepatic, renal, blood, respiratory, or neuropsychiatric diseases;

          7. Malignant tumor, lymphoma, HIV-positive, or hepatitis;

          8. Uncontrolled hypertension (systolic BP &gt;160 mm Hg or a diastolic BP &gt;100 mmHg on at
             least two consecutive readings);

          9. Patients with active bleeding, major surgery or trauma within 3 months and
             cerebrovascular accident within 6 months;

         10. History of anemia (hemoglobin&lt;90g/L) or thrombocytopenia (thrombocyte&lt;90×109/L);

         11. Multi-vessel disease with non-culprit vessel intervention;

         12. Breastfeeding, pregnant, or potentially fertile women;

         13. Patients who have known to be allergic to Shenfu Injection or its components or
             patients with serious adverse effect;

         14. Patients with potential contraindication to CMR;

         15. Participation in other clinical trial in recent 3 months;

         16. Patients who cannot complete this trial or comply with the protocol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Xiao Wang, MD</last_name>
    <phone>86-10-84005253</phone>
    <email>spaceeye123@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beijing Anzhen Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <zip>100029</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shao-Ping Nie, MD, PhD</last_name>
      <phone>86-10-84005256</phone>
      <email>spnie@126.com</email>
    </contact>
    <investigator>
      <last_name>Shao-Ping Nie, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 11, 2016</study_first_submitted>
  <study_first_submitted_qc>March 15, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 16, 2016</study_first_posted>
  <last_update_submitted>October 16, 2017</last_update_submitted>
  <last_update_submitted_qc>October 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Anzhen Hospital</investigator_affiliation>
    <investigator_full_name>Shao-Ping Nie</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>Shenfu Injection</keyword>
  <keyword>Reperfusion Injury</keyword>
  <keyword>Myocardial Protection</keyword>
  <keyword>Percutaneous Coronary Intervention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Reperfusion Injury</mesh_term>
    <mesh_term>ST Elevation Myocardial Infarction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

